Publication Listing for the MeSH term colon-cancer. Found 20 abstracts
Zijoo R, Olszanski AJ, Weinberg DS. Biomarkers and stage II colorectal cancer therapy. Translational Cancer Research. 2016 Jun;5:S84-S86. PMCID: Editorial |
Hyslop T, Weinberg DS, Schulz S, Barkun A, Waldman SA. Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes. Cancer. 2012 May;118(9):2532-40. PMCID: PMC3235256 |
Hyslop T, Weinberg DS, Schulz S, Barkun A, Waldman SA. Analytic lymph node number establishes staging accuracy by occult tumor burden in colorectal cancer. Journal of surgical oncology. 2012 Jul;106(1):24-30. PMCID: PMC3370134 |
Hyslop T, Weinberg DS, Schulz S, Barkun A, Waldman SA. Occult Tumor Burden Predicts Disease Recurrence in Lymph Node-Negative Colorectal Cancer. Clinical Cancer Research. 2011 May;17(10):3293-303. PMCID: PMC3096730 |
Myers RE, Manne SL, Wilfond B, Sifri R, Ziring B, Wolf TA, Cocroft J, Ueland A, Petrich A, Swan H, DiCarlo M, Weinberg DS. A randomized trial of genetic and environmental risk assessment (GERA) for colorectal cancer risk in primary care: Trial design and baseline findings. Contemporary clinical trials. 2011 Jan;32(1):25-31. PMCID: PMC3006063 |
Manne SL, Meropol NJ, Weinberg DS, Vig H, Catts ZA, Manning C, Ross E, Shannon K, Chung DC. Facilitating Informed Decisions Regarding Microsatellite Instability Testing Among High-Risk Individuals Diagnosed With Colorectal Cancer. Journal of Clinical Oncology. 2010 Mar;28(8):1366-72. PMCID: PMC2834496 |
Swoboda RK, Somasundaram R, Caputo L, Berencsi K, von Franzke P, Taylor DD, Marincola FM, Meropol NJ, Sigurdson E, Miller E, Herlyn D. Nucleophosmin is recognized by a cytotoxic T cell line derived from a rectal carcinoma patient. International journal of cancer. 2010 Sep;127(5):1124-30. PMCID: PMCID: PMC2897913 [Available on 2011/9/1] |
Boquoi A, Chen T, Enders GH. Chemoprevention of Mouse Intestinal Tumorigenesis by the Cyclin-Dependent Kinase Inhibitor SNS-032. Cancer Prevention Research. 2009 Sep;2(9):800-6. PMCID: PMC2819381 |
Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C. Rectal Cancer. Journal of the National Comprehensive Cancer Network. 2009 Sep;7(8):838-81. PMCID: not NIH funded |
Ray ME, Bae K, Hussain MH, Hanks GE, Shipley WU, Sandler HM. Potential Surrogate Endpoints for Prostate Cancer Survival: Analysis of a Phase III Randomized Trial. Journal of the National Cancer Institute. 2009 Feb;101(4):228-36. PMCID: PMC2734115 |
Butler LM, Koh WP, Lee HP, Tseng M, Yu MC, London SJ. Prospective study of dietary patterns and persistent cough with phlegm among Chinese Singaporeans. American Journal of Respiratory and Critical Care Medicine. 2006 Feb;173(3):264-70. |
Giantonio BJ, Levy DE, O'Dwyer PJ, Meropol NJ, Catalano PJ, Benson AB. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200. ANNALS OF ONCOLOGY. 2006 Sep;17(9):1399-403. |
Rosen DG, Cai KQ, Luthra R, Liu JS. Immunohistochemical staining of hMLH1 and hMSH2 reflects microsatellite instability status in ovarian carcinoma. MODERN PATHOLOGY. 2006 Nov;19(11):1414-20. |
Birbe R, Palazzo JP, Walters R, Weinberg D, Schutz S, Waldman SA. Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract. Human Pathology. 2005 Feb;36(2):170-9. |
Cohen SJ, Cohen RB, Meropol NJ. Targeting signal transduction pathways in colorectal cancer - More than skin deep. Journal of Clinical Oncology. 2005 Aug 10;23(23):5374-85. |
Purev E, Cai DW, Miller E, Swoboda R, Klein-Szanto A, Marincola FM, Mick R, Otvos L, Wunner W, Birebent B, Somasundaram R, Wikstrand CJ, Bigner D, DeMichele A, Acs G, Berlin JA, Herlyn D. Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Delta EGF-R, and de2-7 EGF-R). Journal of Immunology. 2004 Nov 15;173(10):6472-80. |
Engstrom PF, Benson A, Choti MA, Cohen AM, Doroshow JH, Fuchs C, Kiel K, Martin EW, McGinn C, Petrelli NJ, Posey JA, Skibber JM, Venook A, Yeatman TJ. NCCN Practice Guidelines for colorectal cancer. Oncology-New York. 2000 Nov;14(11A):203-12. |
Tseng M, Ingram DD, Darden R, Ziegler RG, Longnecker MP. Eating frequency and risk of colorectal cancer. Nutrition and Cancer-an International Journal. 2000 Jan;36(2):170-6. |
Garay CA, Engstrom PF. Chemoprevention of colorectal cancer: Dietary and pharmacologic approaches. Oncology-New York. 1999 Jan;13(1):89-97. |
Geller G, Botkin JR, Green MJ, Press N, Biesecker B, Wilfond B, Grana G, Daly MB, Schneider K, Kahn MJ. Genetic testing for susceptibility to adult-onset cancer - The process and content of informed consent. JAMA-Journal of the American Medical Association. 1997 May 14;277(18):1467-74. |
MeSH cloud from publications including the MeSH term colon-cancer
colon-cancer
microsatellite instability
carcinoma
guanylyl cyclase-c
expression
fluorouracil
micrometastases
mortality
identification
familial adenomatous polyposis
women
knowledge
lymph-nodes
african-americans
lynch-syndrome
survival
adjuvant chemotherapy
tumors
follow-up
breast-cancer
oxaliplatin
angiogenesis
marker
preoperative pelvic chemoradiotherapy
mice
recommendations
prospective randomized-trial
controlled clinical-trial
lung carcinomas
phase-i trial
total mesorectal excision
IFL
neoplasm recurrence
reducing morbidity
cells
interventions
egfrviii
dna methylation
vitamin-e
mutations
npm
long-term survival
genes
disparities
confidence-intervals
randomized trial
environmental factors
food-frequency questionnaire
biochemical failure
metastatic colorectal cancer
local excision
uroguanylin
coronary-heart-disease
risk
confers enhanced tumorigenicity
receptors
quantification
prognosis
humanized monoclonal-antibody
therapy oncology group
cyclic-gmp
randomized-trial
cytotoxic t-lymphocytes
line p53 mutations
guanylyl cyclase C
cancer
gene
high-dose bevacizumab
colorectal-cancer
ulcerative-colitis
rectal-cancer
family history
apoptosis-inducing ligand
sphincter preservation
susceptibility
mutation
messenger-rna
diet
ovarian-cancer
mismatch repair
plus fluorouracil
Oncology
factor-kappa-b
systematic reviews
attitudes
polymorphisms
discrimination
human glioblastoma
patient education
NCCN Clinical Practice Guidelines
surgery
obstructive pulmonary-disease
p16(ink4a)
hMSH2
carcinogenesis
vitamins
radiation-therapy
Colorectal neoplasms Decision making-Mass screening-Risk assessment-Genetic screening
computer-assisted-instruction
nutrition examination survey
tumor-development
Pathology
enhanced antitumor-activity
chronic bronchitis asthma-chronic obstructive pulmonary disease-diet-respiratory-signs and symptoms
1st-line treatment
cell
postoperative radiation-therapy
homolog
human tumor-antigens
liver metastasis
gastrointestinal malignancy
lymph-node metastases
nonpolyposis colorectal-cancer
vaccine development
therapy
hMLH1
ovarian carcinoma
immunohistochemistry
iowa womens health
meal frequency
messenger-rna expression
growth-factor receptor
adjuvant therapy
radical prostatectomy
rectal polyps
huntington disease
tissue microarrays
irinotecan
recurrence
randomized-trial evidence
group protocol 92-02
colorectal
activated protein-kinase
time
statistical-method
androgen deprivation
phenotype
cytotoxic T cells colorectal carcinoma patients-antigens-tumor immunity
race
aid
inummohistochemistry
tumor-cells
radiotherapy
disease
participation
intestinal metaplasia
advanced solid tumors
hypermethylation
colorectal liver metastases
lymphocyte clone